-
1
-
-
0346098179
-
History of antibody therapy for non-Hodgkin's lymphoma
-
Forero A, Lobuglio AF. 2003. History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol 30:1-5.
-
(2003)
Semin Oncol
, vol.30
, pp. 1-5
-
-
Forero, A.1
Lobuglio, A.F.2
-
2
-
-
0346328325
-
Rituximab (Rituxan/MabThera): The first decade (1993-2003)
-
Grillo-Lopez AJ. 2003. Rituximab (Rituxan/MabThera): The first decade (1993-2003). Expert Rev Anticancer Ther 3:767-769.
-
(2003)
Expert Rev Anticancer Ther
, vol.3
, pp. 767-769
-
-
Grillo-Lopez, A.J.1
-
3
-
-
0242721899
-
Clinical experience with trastuzumab (herceptin)
-
Vogel CL, Franco SX. 2003. Clinical experience with trastuzumab (herceptin). Breast J 9:452-462.
-
(2003)
Breast J
, vol.9
, pp. 452-462
-
-
Vogel, C.L.1
Franco, S.X.2
-
4
-
-
0036214044
-
The ErbB receptor family: A therapeutic target for cancer
-
de Bono JS, Rowinsky EK. 2002. The ErbB receptor family: A therapeutic target for cancer. Trends Mol Med 8:S19-S26.
-
(2002)
Trends Mol Med
, vol.8
, pp. S19-S26
-
-
De Bono, J.S.1
Rowinsky, E.K.2
-
5
-
-
2442590862
-
New drugs for rheumatoid arthritis
-
Olsen NJ, Stein CM. 2004. New drugs for rheumatoid arthritis. N Engl J Med 350:2167-2179.
-
(2004)
N Engl J Med
, vol.350
, pp. 2167-2179
-
-
Olsen, N.J.1
Stein, C.M.2
-
6
-
-
0029891262
-
The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor
-
Junghans RP, Anderson CL. 1996. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93:5512-5516.
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 5512-5516
-
-
Junghans, R.P.1
Anderson, C.L.2
-
7
-
-
0027398643
-
Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients
-
Gallinger S, Reilly RM, Kirsh JC, Odze RD, Schmocker BJ, Hay K, Polihronis J, Damani MT, Shpitz B, Stern HS. 1993. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 53:271-278.
-
(1993)
Cancer Res
, vol.53
, pp. 271-278
-
-
Gallinger, S.1
Reilly, R.M.2
Kirsh, J.C.3
Odze, R.D.4
Schmocker, B.J.5
Hay, K.6
Polihronis, J.7
Damani, M.T.8
Shpitz, B.9
Stern, H.S.10
-
8
-
-
0001871568
-
Therapeutic applications of monoclonal antibodies for human disease
-
Birch JR, Lennox ES New York: Wiley-Liss
-
Scheinberg DA, Chapman PB. 1995. Therapeutic applications of monoclonal antibodies for human disease. In Monoclonal antibodies: Principles and applications; Birch JR, Lennox ES, Eds. New York: Wiley-Liss, pp 45-105.
-
(1995)
Monoclonal Antibodies: Principles and Applications
, pp. 45-105
-
-
Scheinberg, D.A.1
Chapman, P.B.2
-
9
-
-
0023621441
-
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies
-
Brüggemann M,Williams GT, Bindon CI, Clark MR,Walker MR, Jefferis R, Waldmann H, Neuberger MS. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166:1351-1361.
-
(1987)
J Exp Med
, vol.166
, pp. 1351-1361
-
-
Brüggemann, M.1
Williams, G.T.2
Bindon, C.I.3
Clark, M.R.4
Walker, M.R.5
Jefferis, R.6
Waldmann, H.7
Neuberger, M.S.8
-
10
-
-
0017102773
-
Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement
-
Schumaker VN, Calcott MA, Spiegelberg HL,Müller-Eberhard HJ.1976. Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry 15:5175-5181.
-
(1976)
Biochemistry
, vol.15
, pp. 5175-5181
-
-
Schumaker, V.N.1
Calcott, M.A.2
Spiegelberg, H.L.3
Müller-Eberhard, H.J.4
-
11
-
-
0037379288
-
The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs
-
Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanessian L, Choi EY, Shaffer DJ, Eden PA, Anderson CL. 2003. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 170:3528-3533.
-
(2003)
J Immunol
, vol.170
, pp. 3528-3533
-
-
Roopenian, D.C.1
Christianson, G.J.2
Sproule, T.J.3
Brown, A.C.4
Akilesh, S.5
Jung, N.6
Petkova, S.7
Avanessian, L.8
Choi, E.Y.9
Shaffer, D.J.10
Eden, P.A.11
Anderson, C.L.12
-
12
-
-
34548229364
-
FcRn: The neonatal Fc receptor comes of age
-
Roopenian DC, Shreeram A. 2007. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725.
-
(2007)
Nat Rev Immunol
, vol.7
, pp. 715-725
-
-
Roopenian, D.C.1
Shreeram, A.2
-
13
-
-
0031014785
-
IgG effector mechanisms
-
Clark MR. 1997. IgG effector mechanisms. Chem Immunol 65:88-110.
-
(1997)
Chem Immunol
, vol.65
, pp. 88-110
-
-
Clark, M.R.1
-
14
-
-
0028970836
-
The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding
-
Morgan A, Jones ND, Nesbitt AM, Chaplin L, Bodmer MW, Emtage JS. 1995. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. Immunology 86:319-324.
-
(1995)
Immunology
, vol.86
, pp. 319-324
-
-
Morgan, A.1
Jones, N.D.2
Nesbitt, A.M.3
Chaplin, L.4
Bodmer, M.W.5
Emtage, J.S.6
-
15
-
-
0037013743
-
Interaction sites on human IgG-Fc for FcgammaR: Current models
-
Jefferis R, Lund J. 2002. Interaction sites on human IgG-Fc for FcgammaR: Current models. Immunol Lett 82:57-65.
-
(2002)
Immunol Lett
, vol.82
, pp. 57-65
-
-
Jefferis, R.1
Lund, J.2
-
16
-
-
0024544730
-
Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors
-
Walker MR, Lund J, Thompson KM, Jefferis R. 1989. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J 259:347-353.
-
(1989)
Biochem J
, vol.259
, pp. 347-353
-
-
Walker, M.R.1
Lund, J.2
Thompson, K.M.3
Jefferis, R.4
-
17
-
-
0024438061
-
Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region
-
Tao MH, Morrison SL. 1989. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143:2595-2601.
-
(1989)
J Immunol
, vol.143
, pp. 2595-2601
-
-
Tao, M.H.1
Morrison, S.L.2
-
18
-
-
0037474543
-
Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity
-
Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. 2003.Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325:979-989.
-
(2003)
J Mol Biol
, vol.325
, pp. 979-989
-
-
Krapp, S.1
Mimura, Y.2
Jefferis, R.3
Huber, R.4
Sondermann, P.5
-
19
-
-
0024544730
-
Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors
-
Walker MR, Lund J, Thompson KM, Jefferis R. 1989. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J 259:347-353.
-
(1989)
Biochem J
, vol.259
, pp. 347-353
-
-
Walker, M.R.1
Lund, J.2
Thompson, K.M.3
Jefferis, R.4
-
20
-
-
0017152608
-
Crystallographic structure studies of an IgG molecule and an Fc fragment
-
Huber R, Deisenhofer J, Colman PM, Matsushima M, Palm W.1976. Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature 264:415-420.
-
(1976)
Nature
, vol.264
, pp. 415-420
-
-
Huber, R.1
Deisenhofer, J.2
Colman, P.M.3
Matsushima, M.4
Palm, W.5
-
21
-
-
0035844212
-
The structure of a human type III Fcgamma receptor in complex with Fc
-
Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD.2001. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 276:16469-16477.
-
(2001)
J Biol Chem
, vol.276
, pp. 16469-16477
-
-
Radaev, S.1
Motyka, S.2
Fridman, W.H.3
Sautes-Fridman, C.4
Sun, P.D.5
-
22
-
-
0032488888
-
Crystallographic structure of an intact IgG1 monoclonal antibody
-
Harris LJ, Skaletsky E, McPherson A. 1998. Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol 275:861-872.
-
(1998)
J Mol Biol
, vol.275
, pp. 861-872
-
-
Harris, L.J.1
Skaletsky, E.2
McPherson, A.3
-
23
-
-
0019934863
-
Structural and numerical variations of the carbohydrate moiety of immunoglobulin G
-
Mizuochi T, Taniguchi T, Shimizu A, Kobata A. 1982. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol 129:2016-2020.
-
(1982)
J Immunol
, vol.129
, pp. 2016-2020
-
-
Mizuochi, T.1
Taniguchi, T.2
Shimizu, A.3
Kobata, A.4
-
24
-
-
0023243297
-
Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns
-
Harada H, Kamei M, Tokumoto Y, Yui S, Koyama F, Kochibe N, Endo T, Kobata A. 1987. Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns. Anal Biochem 164:374-381.
-
(1987)
Anal Biochem
, vol.164
, pp. 374-381
-
-
Harada, H.1
Kamei, M.2
Tokumoto, Y.3
Yui, S.4
Koyama, F.5
Kochibe, N.6
Endo, T.7
Kobata, A.8
-
26
-
-
33751253486
-
Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality
-
Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44:1524-1534.
-
(2007)
Mol Immunol
, vol.44
, pp. 1524-1534
-
-
Scallon, B.J.1
Tam, S.H.2
McCarthy, S.G.3
Cai, A.N.4
Raju, T.S.5
-
27
-
-
0028670916
-
Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity
-
Kumpel BM, Rademacher TW, Rook GA, Williams PJ, Wilson IB.1994. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum Antibodies Hybridomas 5:143-151.
-
(1994)
Hum Antibodies Hybridomas
, vol.5
, pp. 143-151
-
-
Kumpel, B.M.1
Rademacher, T.W.2
Rook, G.A.3
Williams, P.J.4
Wilson, I.B.5
-
28
-
-
0033044588
-
Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity
-
Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. 1999.Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17:176-180.
-
(1999)
Nat Biotechnol
, vol.17
, pp. 176-180
-
-
Umãa, P.1
Jean-Mairet, J.2
Moudry, R.3
Amstutz, H.4
Bailey, J.E.5
-
29
-
-
84863440630
-
Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans
-
Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer R. 2012. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs 24:475-487.
-
(2012)
MAbs
, vol.24
, pp. 475-487
-
-
Yu, M.1
Brown, D.2
Reed, C.3
Chung, S.4
Lutman, J.5
Stefanich, E.6
Wong, A.7
Stephan, J.P.8
Bayer, R.9
-
30
-
-
33845590523
-
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types
-
Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M. 2007. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types. Glycobiology 17:104-118.
-
(2007)
Glycobiology
, vol.17
, pp. 104-118
-
-
Kanda, Y.1
Yamada, T.2
Mori, K.3
Okazaki, A.4
Inoue, M.5
Kitajima-Miyama, K.6
Kuni-Kamochi, R.7
Nakano, R.8
Yano, K.9
Kakita, S.10
Shitara, K.11
Satoh, M.12
-
31
-
-
48549090941
-
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
-
Raju TS. 2008. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 20:471-478.
-
(2008)
Curr Opin Immunol
, vol.20
, pp. 471-478
-
-
Raju, T.S.1
-
32
-
-
38549176118
-
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
-
Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. 2008. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 117:244-279.
-
(2008)
Pharmacol Ther
, vol.117
, pp. 244-279
-
-
Tracey, D.1
Klareskog, L.2
Sasso, E.H.3
Salfeld, J.G.4
Tak, P.P.5
-
33
-
-
33845961014
-
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
-
Shih T, Lindley C. 2006. Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779-1802.
-
(2006)
Clin Ther
, vol.28
, pp. 1779-1802
-
-
Shih, T.1
Lindley, C.2
-
35
-
-
0036464719
-
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
-
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758.
-
(2002)
Blood
, vol.99
, pp. 754-758
-
-
Cartron, G.1
Dacheux, L.2
Salles, G.3
Solal-Celigny, P.4
Bardos, P.5
Colombat, P.6
Watier, H.7
-
36
-
-
3042743884
-
Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on the concentration-effect relationship
-
Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. 2004. Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64:4664-4669.
-
(2004)
Cancer Res
, vol.64
, pp. 4664-4669
-
-
Dall'Ozzo, S.1
Tartas, S.2
Paintaud, G.3
Cartron, G.4
Colombat, P.5
Bardos, P.6
Watier, H.7
Thibault, G.8
-
37
-
-
0037289807
-
The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
-
Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ. 2003. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455-459.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 455-459
-
-
Anolik, J.H.1
Campbell, D.2
Felgar, R.E.3
Young, F.4
Sanz, I.5
Rosenblatt, J.6
Looney, R.J.7
-
38
-
-
0642373290
-
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
-
Weng WK, Levy R. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3940-3947
-
-
Weng, W.K.1
Levy, R.2
-
39
-
-
42949157368
-
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
-
Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A. 2008. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1789-1796
-
-
Musolino, A.1
Naldi, N.2
Bortesi, B.3
Pezzuolo, D.4
Capelletti, M.5
Missale, G.6
Laccabue, D.7
Zerbini, A.8
Camisa, R.9
Bisagni, G.10
Neri, T.M.11
Ardizzoni, A.12
-
40
-
-
1342282157
-
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia
-
Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP. 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172:3280-3288.
-
(2004)
J Immunol
, vol.172
, pp. 3280-3288
-
-
Kennedy, A.D.1
Beum, P.V.2
Solga, M.D.3
DiLillo, D.J.4
Lindorfer, M.A.5
Hess, C.E.6
Densmore, J.J.7
Williams, M.E.8
Taylor, R.P.9
-
41
-
-
38949185742
-
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study
-
Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Robak T. 2008. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study. Blood 111:1094-1100.
-
(2008)
Blood
, vol.111
, pp. 1094-1100
-
-
Coiffier, B.1
Lepretre, S.2
Pedersen, L.M.3
Gadeberg, O.4
Fredriksen, H.5
Van Oers, M.H.6
Wooldridge, J.7
Kloczko, J.8
Holowiecki, J.9
Hellmann, A.10
Walewski, J.11
Flensburg, M.12
Petersen, J.13
Robak, T.14
-
42
-
-
0019934863
-
Structural and numerical variations of the carbohydrate moiety of immunoglobulin G
-
Mizuochi T, Taniguchi T, Shimizu A, Kobata A. 1982. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol 129:2016-2020.
-
(1982)
J Immunol
, vol.129
, pp. 2016-2020
-
-
Mizuochi, T.1
Taniguchi, T.2
Shimizu, A.3
Kobata, A.4
-
43
-
-
0023243297
-
Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns
-
Harada H, Kamei M, Tokumoto Y, Yui S, Koyama F, Kochibe N, Endo T, Kobata A. 1987. Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns. Anal Biochem 164:374-381.
-
(1987)
Anal Biochem
, vol.164
, pp. 374-381
-
-
Harada, H.1
Kamei, M.2
Tokumoto, Y.3
Yui, S.4
Koyama, F.5
Kochibe, N.6
Endo, T.7
Kobata, A.8
-
44
-
-
0037178791
-
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibodydependent cellular toxicity
-
Shields RL, Lai J,Keck R, O'Connell LY, Hong K, Meng YG,Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibodydependent cellular toxicity. J Biol Chem 277:26733-26740.
-
(2002)
J Biol Chem
, vol.277
, pp. 26733-26740
-
-
Shields, R.L.1
Lai, J.2
Keck, R.3
O'Connell, L.Y.4
Hong, K.5
Meng, Y.G.6
Weikert, S.H.7
Presta, L.G.8
-
45
-
-
0037474276
-
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
-
Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278:3466-3473.
-
(2003)
J Biol Chem
, vol.278
, pp. 3466-3473
-
-
Shinkawa, T.1
Nakamura, K.2
Yamane, N.3
Shoji-Hosaka, E.4
Kanda, Y.5
Sakurada, M.6
Uchida, K.7
Anazawa, H.8
Satoh, M.9
Yamasaki, M.10
Hanai, N.11
Shitara, K.12
-
46
-
-
12144289636
-
Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma
-
Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K. 2004. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64:2127-2133.
-
(2004)
Cancer Res
, vol.64
, pp. 2127-2133
-
-
Niwa, R.1
Shoji-Hosaka, E.2
Sakurada, M.3
Shinkawa, T.4
Uchida, K.5
Nakamura, K.6
Matsushima, K.7
Ueda, R.8
Hanai, N.9
Shitara, K.10
-
47
-
-
4644245850
-
Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity
-
Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R,Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M. 2004. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87:614-622.
-
(2004)
Biotechnol Bioeng
, vol.87
, pp. 614-622
-
-
Yamane-Ohnuki, N.1
Kinoshita, S.2
Inoue-Urakubo, M.3
Kusunoki, M.4
Iida, S.5
Nakano, R.6
Wakitani, M.7
Niwa, R.8
Sakurada, M.9
Uchida, K.10
Shitara, K.11
Satoh, M.12
-
48
-
-
33646070900
-
Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous $ 1, 4-N-acetylglucosaminyltransferase III and Golgi a-mannosidase II
-
Ferrara C, Brunker P, Suter T, Moser S, Puntener U, Umana P.2006. Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous $ 1, 4-N-acetylglucosaminyltransferase III and Golgi a-mannosidase II. Biotechnol Bioeng 93:851-861.
-
(2006)
Biotechnol Bioeng
, vol.93
, pp. 851-861
-
-
Ferrara, C.1
Brunker, P.2
Suter, T.3
Moser, S.4
Puntener, U.5
Umana, P.6
-
49
-
-
32344449790
-
Optimization of humanized IgGs in glycoengineered Pichia pastoris
-
Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, Bobrowicz P, Choi BK, Cook WJ, Cukan M, Houston-Cummings NR, Davidson R, Gong B, Hamilton SR, Hoopes JP, Jiang Y, Kim N, Mansfield R, Nett JH, Rios S, Strawbridge R, Wildt S, Gerngross TU. 2006.Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 24:210-215.
-
(2006)
Nat Biotechnol
, vol.24
, pp. 210-215
-
-
Li, H.1
Sethuraman, N.2
Stadheim, T.A.3
Zha, D.4
Prinz, B.5
Ballew, N.6
Bobrowicz, P.7
Choi, B.K.8
Cook, W.J.9
Cukan, M.10
Houston-Cummings, N.R.11
Davidson, R.12
Gong, B.13
Hamilton, S.R.14
Hoopes, J.P.15
Jiang, Y.16
Kim, N.17
Mansfield, R.18
Nett, J.H.19
Rios, S.20
Strawbridge, R.21
Wildt, S.22
Gerngross, T.U.23
more..
-
50
-
-
33845711353
-
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor
-
Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, Black A, Passmore D, Moldovan-Loomis C, Srinivasan M, Cuison S, Cardarelli PM, Dickey LF. 2006. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 24:1591-1597.
-
(2006)
Nat Biotechnol
, vol.24
, pp. 1591-1597
-
-
Cox, K.M.1
Sterling, J.D.2
Regan, J.T.3
Gasdaska, J.R.4
Frantz, K.K.5
Peele, C.G.6
Black, A.7
Passmore, D.8
Moldovan-Loomis, C.9
Srinivasan, M.10
Cuison, S.11
Cardarelli, P.M.12
Dickey, L.F.13
-
51
-
-
34447301500
-
In vivo glycoengineered antibody with improved lytic potential produced by an innovative non-mammalian expression system
-
Schuster M, Jost W, Mudde GC,Wiederkum S, Schwager C, Janzek E, Altmann F, Stadlmann J, Stemmer C, Gorr G. 2007. In vivo glycoengineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. Biotechnol J 2:700-708.
-
(2007)
Biotechnol J
, vol.2
, pp. 700-708
-
-
Schuster, M.1
Jost, W.2
Mudde, G.C.3
Wiederkum, S.4
Schwager, C.5
Janzek, E.6
Altmann, F.7
Stadlmann, J.8
Stemmer, C.9
Gorr, G.10
-
52
-
-
34047142084
-
Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1
-
Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, Otaki S, Satoh M, Shitara K, Kato K. 2007. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 368:767-779.
-
(2007)
J Mol Biol
, vol.368
, pp. 767-779
-
-
Matsumiya, S.1
Yamaguchi, Y.2
Saito, J.3
Nagano, M.4
Sasakawa, H.5
Otaki, S.6
Satoh, M.7
Shitara, K.8
Kato, K.9
-
53
-
-
39149106011
-
Structural characterization of a mutated, ADCC-enhanced human Fc fragment
-
Oganesyan V, Damschroder MM, Leach W, Wu H, Dall'Acqua WF.2008. Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol 45:1872-1882.
-
(2008)
Mol Immunol
, vol.45
, pp. 1872-1882
-
-
Oganesyan, V.1
Damschroder, M.M.2
Leach, W.3
Wu, H.4
Dall'Acqua, W.F.5
-
54
-
-
79961233787
-
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose
-
Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P,Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, Umaña P, Benz J. 2011. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA 108:12669-12674.
-
(2011)
Proc Natl Acad Sci USA
, vol.108
, pp. 12669-12674
-
-
Ferrara, C.1
Grau, S.2
Jäger, C.3
Sondermann, P.4
Brünker, P.5
Waldhauer, I.6
Hennig, M.7
Ruf, A.8
Rufer, A.C.9
Stihle, M.10
Umãa, P.11
Benz, J.12
-
55
-
-
80054944116
-
Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans
-
Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, Masuda K, Satoh M, Kato K. 2011. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 16:1071-1080.
-
(2011)
Genes Cells
, vol.16
, pp. 1071-1080
-
-
Mizushima, T.1
Yagi, H.2
Takemoto, E.3
Shibata-Koyama, M.4
Isoda, Y.5
Iida, S.6
Masuda, K.7
Satoh, M.8
Kato, K.9
-
56
-
-
16844381436
-
Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibodydependent cellular cytotoxicity induction at lower antigen density
-
Niwa R, Sakurada M,Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K. 2005. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibodydependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11:2327-2336.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 2327-2336
-
-
Niwa, R.1
Sakurada, M.2
Kobayashi, Y.3
Uehara, A.4
Matsushima, K.5
Ueda, R.6
Nakamura, K.7
Shitara, K.8
-
57
-
-
3042606229
-
Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: Possible inhibitory effect of IgG
-
Vugmeyster Y, Howell K. 2004. Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: Possible inhibitory effect of IgG. Int Immunopharmacol 24:1117-1124.
-
(2004)
Int Immunopharmacol
, vol.24
, pp. 1117-1124
-
-
Vugmeyster, Y.1
Howell, K.2
-
58
-
-
30344434022
-
High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibodydependent cellular cytotoxicity by excess endogenous immunoglobulin G
-
Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS. 2006. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibodydependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 43:1183-1193.
-
(2006)
Mol Immunol
, vol.43
, pp. 1183-1193
-
-
Preithner, S.1
Elm, S.2
Lippold, S.3
Locher, M.4
Wolf, A.5
Da Silva, A.J.6
Baeuerle, P.A.7
Prang, N.S.8
-
59
-
-
33646740982
-
Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa
-
Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M. 2006. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 12:2879-2887.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 2879-2887
-
-
Iida, S.1
Misaka, H.2
Inoue, M.3
Shibata, M.4
Nakano, R.5
Yamane-Ohnuki, N.6
Wakitani, M.7
Yano, K.8
Shitara, K.9
Satoh, M.10
-
60
-
-
59749104215
-
Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils
-
Shibata-Koyama M, Iida S, Misaka H, Mori K, Yano K, Shitara K, Satoh M. 2009. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol 37:309-321.
-
(2009)
Exp Hematol
, vol.37
, pp. 309-321
-
-
Shibata-Koyama, M.1
Iida, S.2
Misaka, H.3
Mori, K.4
Yano, K.5
Shitara, K.6
Satoh, M.7
-
61
-
-
0028091566
-
Improved tumor targeting with chemically cross-linked recombinant antibody fragments
-
King DJ, Turner A, Farnsworth AP, Adair JR, Owens RJ, Pedley RB, Baldock D, Proudfoot KA, Lawson AD, Beeley NR, Millar K, Millican TA, Boyce BA, Antoniw P, Mountain A, Begent RH, Yarranton GT.1994. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 54:6176-6185.
-
(1994)
Cancer Res
, vol.54
, pp. 6176-6185
-
-
King, D.J.1
Turner, A.2
Farnsworth, A.P.3
Adair, J.R.4
Owens, R.J.5
Pedley, R.B.6
Baldock, D.7
Proudfoot, K.A.8
Lawson, A.D.9
Beeley, N.R.10
Millar, K.11
Millican, T.A.12
Boyce, B.A.13
Antoniw, P.14
Mountain, A.15
Begent, R.H.16
Yarranton, G.T.17
-
62
-
-
0030806221
-
Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells
-
Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES. 1997. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci USA 94:7509-7514.
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, pp. 7509-7514
-
-
Ghetie, M.A.1
Podar, E.M.2
Ilgen, A.3
Gordon, B.E.4
Uhr, J.W.5
Vitetta, E.S.6
-
63
-
-
0035282930
-
Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin
-
Ghetie MA, Bright H, Vitetta ES. 2001. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97:1392-1398.
-
(2001)
Blood
, vol.97
, pp. 1392-1398
-
-
Ghetie, M.A.1
Bright, H.2
Vitetta, E.S.3
-
64
-
-
77950074334
-
Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcgammaRIIIb on neutrophils
-
Nakagawa T, Natsume A, Satoh M, Niwa R. 2010. Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcgammaRIIIb on neutrophils. Leuk Res 34:666-671.
-
(2010)
Leuk Res
, vol.34
, pp. 666-671
-
-
Nakagawa, T.1
Natsume, A.2
Satoh, M.3
Niwa, R.4
-
65
-
-
0037033448
-
Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells
-
Dhodapkar KM, Krasovsky J,Williamson B, Dhodapkar MV. 2002.Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195:125-133.
-
(2002)
J Exp Med
, vol.195
, pp. 125-133
-
-
Dhodapkar, K.M.1
Krasovsky, J.2
Williamson, B.3
Dhodapkar, M.V.4
-
66
-
-
34248213007
-
Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance
-
Harbers SO1, Crocker A, Catalano G, D'Agati V, Jung S, Desai DD, Clynes R. 2007. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 117:1361-1369.
-
(2007)
J Clin Invest
, vol.117
, pp. 1361-1369
-
-
Harbers, S.O.1
Crocker, A.2
Catalano, G.3
D'Agati, V.4
Jung, S.5
Desai, D.D.6
Clynes, R.7
-
67
-
-
77956545725
-
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
-
Abès R, Gélizé E, Fridman WH, Teillaud JL. 2010. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116:926-934.
-
(2010)
Blood
, vol.116
, pp. 926-934
-
-
Abès, R.1
Gélizé, E.2
Fridman, W.H.3
Teillaud, J.L.4
-
68
-
-
34548842227
-
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy
-
Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R. 2007. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 13:5133-5143.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 5133-5143
-
-
Taylor, C.1
Hershman, D.2
Shah, N.3
Suciu-Foca, N.4
Petrylak, D.P.5
Taub, R.6
Vahdat, L.7
Cheng, B.8
Pegram, M.9
Knutson, K.L.10
Clynes, R.11
-
69
-
-
78049427830
-
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape
-
Ferris RL, Jaffee EM, Ferrone S. 2010. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape. J Clin Oncol 28:4390-4399.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4390-4399
-
-
Ferris, R.L.1
Jaffee, E.M.2
Ferrone, S.3
-
70
-
-
0029946383
-
'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization
-
Ridgway JB, Presta LG, Carter P. 1996. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9:617-621.
-
(1996)
Protein Eng
, vol.9
, pp. 617-621
-
-
Ridgway, J.B.1
Presta, L.G.2
Carter, P.3
-
71
-
-
0031876578
-
An efficient route to human bispecific IgG
-
Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. 1998. An efficient route to human bispecific IgG. Nat Biotechnol 1:677-681.
-
(1998)
Nat Biotechnol
, vol.1
, pp. 677-681
-
-
Merchant, A.M.1
Zhu, Z.2
Yuan, J.Q.3
Goddard, A.4
Adams, C.W.5
Presta, L.G.6
Carter, P.7
-
72
-
-
77954674574
-
Catumaxomab-trifunctional anti-EpCAM antibody used to treat malignant ascites
-
Bokemeyer C. 2010. Catumaxomab-trifunctional anti-EpCAM antibody used to treat malignant ascites. Expert Opin Biol Ther 10:1259-1269.
-
(2010)
Expert Opin Biol Ther
, vol.10
, pp. 1259-1269
-
-
Bokemeyer, C.1
-
73
-
-
84855586532
-
Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
-
Ott MG, Marmé F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D. 2012. Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer 130:2195-2203.
-
(2012)
Int J Cancer
, vol.130
, pp. 2195-2203
-
-
Ott, M.G.1
Marmé, F.2
Moldenhauer, G.3
Lindhofer, H.4
Hennig, M.5
Spannagl, R.6
Essing, M.M.7
Linke, R.8
Seimetz, D.9
-
75
-
-
84922819670
-
Confirmatory open-label, singlearm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL)
-
Abstract 7005
-
Topp MS, Goekbuget N, Stein AS, Bargou RC, Dombret H, Fielding AK, Ribera JM, Foà R, Zugmaier G, Holland C, Maniar T, Huber B, Nagorsen D, Kantarjian HM. 2014. Confirmatory open-label, singlearm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL). Annual Meeting of American Society of Clinical Oncology, Abstract 7005.
-
(2014)
Annual Meeting of American Society of Clinical Oncology
-
-
Topp, M.S.1
Goekbuget, N.2
Stein, A.S.3
Bargou, R.C.4
Dombret, H.5
Fielding, A.K.6
Ribera, J.M.7
Foà, R.8
Zugmaier, G.9
Holland, C.10
Maniar, T.11
Huber, B.12
Nagorsen, D.13
Kantarjian, H.M.14
-
76
-
-
28744445538
-
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
-
Brischwein K, Schlereth B, Guller B, Steiger C,Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA.2006. MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 43:1129-1143.
-
(2006)
Mol Immunol
, vol.43
, pp. 1129-1143
-
-
Brischwein, K.1
Schlereth, B.2
Guller, B.3
Steiger, C.4
Wolf, A.5
Lutterbuese, R.6
Offner, S.7
Locher, M.8
Urbig, T.9
Raum, T.10
Kleindienst, P.11
Wimberger, P.12
Kimmig, R.13
Fichtner, I.14
Kufer, P.15
Hofmeister, R.16
Da Silva, A.J.17
Baeuerle, P.A.18
-
77
-
-
67449097665
-
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA
-
Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P. 2009. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 32:341-352.
-
(2009)
J Immunother
, vol.32
, pp. 341-352
-
-
Lutterbuese, R.1
Raum, T.2
Kischel, R.3
Lutterbuese, P.4
Schlereth, B.5
Schaller, E.6
Mangold, S.7
Rau, D.8
Meier, P.9
Kiener, P.A.10
Mulgrew, K.11
Oberst, M.D.12
Hammond, S.A.13
Baeuerle, P.A.14
Kufer, P.15
-
78
-
-
84871360414
-
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody crossreactive with non-human primate antigens
-
Hoffmann P, Brandl C, Schuhmacher J, Mueller P, Finnern R, Fuergut M, Zopf D, Slootstra JW, Baeuerle PA, Rattel B, Kufer P. 2012. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody crossreactive with non-human primate antigens. Mol Cancer Ther 11:2664-2673.
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 2664-2673
-
-
Hoffmann, P.1
Brandl, C.2
Schuhmacher, J.3
Mueller, P.4
Finnern, R.5
Fuergut, M.6
Zopf, D.7
Slootstra, J.W.8
Baeuerle, P.A.9
Rattel, B.10
Kufer, P.11
-
79
-
-
84922783939
-
Targeting CD123 in leukemic stem cells using dual affinity retargeting molecules (DARTs)
-
Abstract 360
-
th Annual Meeting of American Society of Hematology, Abstract 360.
-
(2013)
55th Annual Meeting of American Society of Hematology
-
-
Hussaini Mh, A.L.1
Ritchey, J.2
Rettig, M.P.3
Eissenberg, L.4
Uy, G.L.5
Chichili, G.6
Moore, P.A.7
Johnson, S.8
Collins, L.9
Bonvini, E.10
DiPersio, J.F.11
-
80
-
-
77954757304
-
Effector cell recruitment with novel Fvbased dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion
-
Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, Yang Y, Jin L, Ciccarone V, Moore PA, Koenig S, Bonvini E. 2010. Effector cell recruitment with novel Fvbased dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 399:436-449.
-
(2010)
J Mol Biol
, vol.399
, pp. 436-449
-
-
Johnson, S.1
Burke, S.2
Huang, L.3
Gorlatov, S.4
Li, H.5
Wang, W.6
Zhang, W.7
Tuaillon, N.8
Rainey, J.9
Barat, B.10
Yang, Y.11
Jin, L.12
Ciccarone, V.13
Moore, P.A.14
Koenig, S.15
Bonvini, E.16
-
81
-
-
33744803712
-
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
-
Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marm é A, Korfel A, Jäger M, Lindhofer H, Sommer H, Thiel E, Untch M. 2006. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 12:3085-3091.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 3085-3091
-
-
Kiewe, P.1
Hasmüller, S.2
Kahlert, S.3
Heinrigs, M.4
Rack, B.5
Marm É, A.6
Korfel, A.7
Jäger, M.8
Lindhofer, H.9
Sommer, H.10
Thiel, E.11
Untch, M.12
-
82
-
-
0034744176
-
Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors
-
Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV, Lum LG. 2001. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res 10:247-260.
-
(2001)
J Hematother Stem Cell Res
, vol.10
, pp. 247-260
-
-
Sen, M.1
Wankowski, D.M.2
Garlie, N.K.3
Siebenlist, R.E.4
Van Epps, D.5
LeFever, A.V.6
Lum, L.G.7
-
83
-
-
15244363849
-
T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro
-
Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG. 2005. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 33:452-459.
-
(2005)
Exp Hematol
, vol.33
, pp. 452-459
-
-
Gall, J.M.1
Davol, P.A.2
Grabert, R.C.3
Deaver, M.4
Lum, L.G.5
-
84
-
-
84956786222
-
Dual inhibition of Ang-2 and VEGF via a novel human bispecific bivalent IgG1 CrossMAb shows potent anti-angiogenic, antitumoral, and antimetastatic efficacy and leads to a reduced side effect profile compared to single therapies
-
Abstract 2319
-
rd Annual Meeting of American Association of Cancer Research, Abstract 2319.
-
(2012)
103rd Annual Meeting of American Association of Cancer Research
-
-
Thomas, M.1
Kienast, Y.2
Scheuer, W.3
Lorenzon, E.4
Herting, F.5
Odin, M.6
Schaefer, W.7
Regula, J.T.8
Stubenrauch, K.-G.9
Klein, C.10
-
85
-
-
84872525097
-
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation
-
Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM. 2013. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 73:824-833.
-
(2013)
Cancer Res
, vol.73
, pp. 824-833
-
-
Huang, S.1
Li, C.2
Armstrong, E.A.3
Peet, C.R.4
Saker, J.5
Amler, L.C.6
Sliwkowski, M.X.7
Harari, P.M.8
-
86
-
-
84859409756
-
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3
-
McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB. 2012. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 11:582-593.
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 582-593
-
-
McDonagh, C.F.1
Huhalov, A.2
Harms, B.D.3
Adams, S.4
Paragas, V.5
Oyama, S.6
Zhang, B.7
Luus, L.8
Overland, R.9
Nguyen, S.10
Gu, J.11
Kohli, N.12
Wallace, M.13
Feldhaus, M.J.14
Kudla, A.J.15
Schoeberl, B.16
Nielsen, U.B.17
-
87
-
-
84922782339
-
Generation of a tetravalent bispecific antibody against IL4 and IL13 for the treatment of idiopathic pulmonary fibrosis
-
Rao E, Li D, Underwood S, Mikol V, Davison M, Kruip J. 2012. Generation of a tetravalent bispecific antibody against IL4 and IL13 for the treatment of idiopathic pulmonary fibrosis. MAbs 4:14-16.
-
(2012)
MAbs
, vol.4
, pp. 14-16
-
-
Rao, E.1
Li, D.2
Underwood, S.3
Mikol, V.4
Davison, M.5
Kruip, J.6
-
88
-
-
33645500289
-
Antibodymaytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
-
Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blättler WA. 2006. Antibodymaytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426-4433.
-
(2006)
Cancer Res
, vol.66
, pp. 4426-4433
-
-
Erickson, H.K.1
Park, P.U.2
Widdison, W.C.3
Kovtun, Y.V.4
Garrett, L.M.5
Hoffman, K.6
Lutz, R.J.7
Goldmacher, V.S.8
Blättler, W.A.9
-
89
-
-
10744222473
-
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
-
Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA,Wahl AF, Meyer DL, Senter PD. 2003. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778-784.
-
(2003)
Nat Biotechnol
, vol.21
, pp. 778-784
-
-
Doronina, S.O.1
Toki, B.E.2
Torgov, M.Y.3
Mendelsohn, B.A.4
Cerveny, C.G.5
Chace, D.F.6
DeBlanc, R.L.7
Gearing, R.P.8
Bovee, T.D.9
Siegall, C.B.10
Francisco, J.A.11
Wahl, A.F.12
Meyer, D.L.13
Senter, P.D.14
-
90
-
-
0036007598
-
An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker
-
Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, Bernstein I. 2002. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 13:40-46.
-
(2002)
Bioconjug Chem
, vol.13
, pp. 40-46
-
-
Hamann, P.R.1
Hinman, L.M.2
Beyer, C.F.3
Lindh, D.4
Upeslacis, J.5
Flowers, D.A.6
Bernstein, I.7
-
91
-
-
74949139946
-
Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates
-
Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, Singh R. 2010. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21:84-92.
-
(2010)
Bioconjug Chem
, vol.21
, pp. 84-92
-
-
Erickson, H.K.1
Widdison, W.C.2
Mayo, M.F.3
Whiteman, K.4
Audette, C.5
Wilhelm, S.D.6
Singh, R.7
-
92
-
-
34547935736
-
Cell killing by antibody-drug conjugates
-
Kovtun YV, Goldmacher VS. 2007. Cell killing by antibody-drug conjugates. Cancer Lett 255:232-240.
-
(2007)
Cancer Lett
, vol.255
, pp. 232-240
-
-
Kovtun, Y.V.1
Goldmacher, V.S.2
-
93
-
-
84879591299
-
The antibody-drug conjugate: An enabling modality for natural product-based cancer therapeutics
-
Gerber HP, Koehn FE, Abraham RT. 2013. The antibody-drug conjugate: An enabling modality for natural product-based cancer therapeutics. Nat Prod Rep 30:625-639.
-
(2013)
Nat Prod Rep
, vol.30
, pp. 625-639
-
-
Gerber, H.P.1
Koehn, F.E.2
Abraham, R.T.3
-
94
-
-
77957590621
-
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer
-
Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX. 2010. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 16:4769-4778.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4769-4778
-
-
Junutula, J.R.1
Flagella, K.M.2
Graham, R.A.3
Parsons, K.L.4
Ha, E.5
Raab, H.6
Bhakta, S.7
Nguyen, T.8
Dugger, D.L.9
Li, G.10
Mai, E.11
Lewis Phillips, G.D.12
Hiraragi, H.13
Fuji, R.N.14
Tibbitts, J.15
Vandlen, R.16
Spencer, S.D.17
Scheller, R.H.18
Polakis, P.19
Sliwkowski, M.X.20
more..
-
95
-
-
49449087300
-
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
-
Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD,Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W. 2008. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925-932.
-
(2008)
Nat Biotechnol
, vol.26
, pp. 925-932
-
-
Junutula, J.R.1
Raab, H.2
Clark, S.3
Bhakta, S.4
Leipold, D.D.5
Weir, S.6
Chen, Y.7
Simpson, M.8
Tsai, S.P.9
Dennis, M.S.10
Lu, Y.11
Meng, Y.G.12
Ng, C.13
Yang, J.14
Lee, C.C.15
Duenas, E.16
Gorrell, J.17
Katta, V.18
Kim, A.19
McDorman, K.20
Flagella, K.21
Venook, R.22
Ross, S.23
Spencer, S.D.24
Lee Wong, W.25
Lowman, H.B.26
Vandlen, R.27
Sliwkowski, M.X.28
Scheller, R.H.29
Polakis, P.30
Mallet, W.31
more..
-
96
-
-
84922832559
-
-
Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, Phuong T, Barnett R, Hehli B, Song F, DeGuzman MJ, Ensari S, Pinkstaff JK, Sullivan LM, Biroc SL, Cho H, Schultz PG, DiJoseph J, Dougher M
-
Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, Phuong T, Barnett R, Hehli B, Song F, DeGuzman MJ, Ensari S, Pinkstaff JK, Sullivan LM, Biroc SL, Cho H, Schultz PG, DiJoseph J, Dougher M,
-
-
-
-
97
-
-
84893452692
-
A general approach to site-specific antibody drug conjugates
-
Ma D, Dushin R, Leal M, Tchistiakova L, Feyfant E, Gerber HP, Sapra P. 2014. A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci USA 111:1766-1771.
-
(2014)
Proc Natl Acad Sci USA
, vol.111
, pp. 1766-1771
-
-
Ma, D.1
Dushin, R.2
Leal, M.3
Tchistiakova, L.4
Feyfant, E.5
Gerber, H.P.6
Sapra, P.7
-
98
-
-
84875467346
-
Brentuximab vedotin: A CD30-directed antibody-cytotoxic drug conjugate
-
Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK. 2013. Brentuximab vedotin: A CD30-directed antibody-cytotoxic drug conjugate. Pharmacotherapy 33:93-104.
-
(2013)
Pharmacotherapy
, vol.33
, pp. 93-104
-
-
Newland, A.M.1
Li, J.X.2
Wasco, L.E.3
Aziz, M.T.4
Lowe, D.K.5
-
99
-
-
84875204170
-
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
-
Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K. 2013. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin 29:405-414.
-
(2013)
Curr Med Res Opin
, vol.29
, pp. 405-414
-
-
Boyraz, B.1
Sendur, M.A.2
Aksoy, S.3
Babacan, T.4
Roach, E.C.5
Kizilarslanoglu, M.C.6
Petekkaya, I.7
Altundag, K.8
-
100
-
-
31544455876
-
Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
-
DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK. 2006. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 12:242-249.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 242-249
-
-
DiJoseph, J.F.1
Dougher, M.M.2
Kalyandrug, L.B.3
Armellino, D.C.4
Boghaert, E.R.5
Hamann, P.R.6
Moran, J.K.7
Damle, N.K.8
-
101
-
-
67449119398
-
The monoclonal antibody nBT062 conjugated to cytotoxicMaytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo
-
Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dälken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC. 2009. The monoclonal antibody nBT062 conjugated to cytotoxicMaytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 15:4028-4037.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4028-4037
-
-
Ikeda, H.1
Hideshima, T.2
Fulciniti, M.3
Lutz, R.J.4
Yasui, H.5
Okawa, Y.6
Kiziltepe, T.7
Vallet, S.8
Pozzi, S.9
Santo, L.10
Perrone, G.11
Tai, Y.T.12
Cirstea, D.13
Raje, N.S.14
Uherek, C.15
Dälken, B.16
Aigner, S.17
Osterroth, F.18
Munshi, N.19
Richardson, P.20
Anderson, K.C.21
more..
-
102
-
-
77950835018
-
Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer
-
Naumovski L, Junutula JR. 2010. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 12:248-257.
-
(2010)
Curr Opin Mol Ther
, vol.12
, pp. 248-257
-
-
Naumovski, L.1
Junutula, J.R.2
-
103
-
-
84880072016
-
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma
-
Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D,Williams M, Ho W, Ebens A, Prabhu S, Polson AG. 2013. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther 12:1255-1265.
-
(2013)
Mol Cancer Ther
, vol.12
, pp. 1255-1265
-
-
Li, D.1
Poon, K.A.2
Yu, S.F.3
Dere, R.4
Go, M.5
Lau, J.6
Zheng, B.7
Elkins, K.8
Danilenko, D.9
Kozak, K.R.10
Chan, P.11
Chuh, J.12
Shi, X.13
Nazzal, D.14
Fuh, F.15
McBride, J.16
Ramakrishnan, V.17
De Tute, R.18
Rawstron, A.19
Jack, A.S.20
Deng, R.21
Chu, Y.W.22
Dornan, D.23
Williams, M.24
Ho, W.25
Ebens, A.26
Prabhu, S.27
Polson, A.G.28
more..
-
104
-
-
70350494468
-
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
-
Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG. 2009. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114:2721-2729.
-
(2009)
Blood
, vol.114
, pp. 2721-2729
-
-
Dornan, D.1
Bennett, F.2
Chen, Y.3
Dennis, M.4
Eaton, D.5
Elkins, K.6
French, D.7
Go, M.A.8
Jack, A.9
Junutula, J.R.10
Koeppen, H.11
Lau, J.12
McBride, J.13
Rawstron, A.14
Shi, X.15
Yu, N.16
Yu, S.F.17
Yue, P.18
Zheng, B.19
Ebens, A.20
Polson, A.G.21
more..
-
105
-
-
22344432668
-
Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys
-
Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, Hansen HJ, Horak ID, Griffiths GL, Goldenberg DM. 2005. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 11:5257-5264.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 5257-5264
-
-
Sapra, P.1
Stein, R.2
Pickett, J.3
Qu, Z.4
Govindan, S.V.5
Cardillo, T.M.6
Hansen, H.J.7
Horak, I.D.8
Griffiths, G.L.9
Goldenberg, D.M.10
-
107
-
-
84863470971
-
Marketing approval of mogamulizumab: A triumph for glyco-engineering
-
Beck A, Reichert JM. 2012. Marketing approval of mogamulizumab: A triumph for glyco-engineering. MAbs 4:419-425.
-
(2012)
MAbs
, vol.4
, pp. 419-425
-
-
Beck, A.1
Reichert, J.M.2
-
108
-
-
84906092974
-
Obinutuzumab: A new class of anti-CD20 monoclonal antibody
-
Gagez AL, Cartron G. 2014. Obinutuzumab: A new class of anti-CD20 monoclonal antibody. Curr Opin Oncol 26(5):484-491.
-
(2014)
Curr Opin Oncol
, vol.26
, Issue.5
, pp. 484-491
-
-
Gagez, A.L.1
Cartron, G.2
-
109
-
-
77951561987
-
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
-
Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umaña P. 2010. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393-4402.
-
(2010)
Blood
, vol.115
, pp. 4393-4402
-
-
Mössner, E.1
Brünker, P.2
Moser, S.3
Püntener, U.4
Schmidt, C.5
Herter, S.6
Grau, R.7
Gerdes, C.8
Nopora, A.9
Van Puijenbroek, E.10
Ferrara, C.11
Sondermann, P.12
Jäger, C.13
Strein, P.14
Fertig, G.15
Friess, T.16
Schüll, C.17
Bauer, S.18
Dal Porto, J.19
Del Nagro, C.20
Dabbagh, K.21
Dyer, M.J.22
Poppema, S.23
Klein, C.24
Umãa, P.25
more..
-
110
-
-
77952733788
-
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibodydependent cell-mediated cytotoxicity function
-
Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'Acqua WW, Stephens GL, Erjefalt JS, Bjermer L, Humbles AA, Gossage D, Wu H, Kiener PA, Spitalny GL, Mackay CR, Molfino NA, Coyle AJ. 2010. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibodydependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125:1344-1353.
-
(2010)
J Allergy Clin Immunol
, vol.125
, pp. 1344-1353
-
-
Kolbeck, R.1
Kozhich, A.2
Koike, M.3
Peng, L.4
Andersson, C.K.5
Damschroder, M.M.6
Reed, J.L.7
Woods, R.8
Dall'Acqua, W.W.9
Stephens, G.L.10
Erjefalt, J.S.11
Bjermer, L.12
Humbles, A.A.13
Gossage, D.14
Wu, H.15
Kiener, P.A.16
Spitalny, G.L.17
Mackay, C.R.18
Molfino, N.A.19
Coyle, A.J.20
more..
-
111
-
-
77957244161
-
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody
-
Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, Evans K, Sims GP, Pfarr DS, Bowen MA, Dall'Acqua W, Shlomchik M, Tedder TF, Kiener P, Jallal B, Wu H, Coyle AJ. 2010. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 335:213-222.
-
(2010)
J Pharmacol Exp Ther
, vol.335
, pp. 213-222
-
-
Herbst, R.1
Wang, Y.2
Gallagher, S.3
Mittereder, N.4
Kuta, E.5
Damschroder, M.6
Woods, R.7
Rowe, D.C.8
Cheng, L.9
Cook, K.10
Evans, K.11
Sims, G.P.12
Pfarr, D.S.13
Bowen, M.A.14
Dall'Acqua, W.15
Shlomchik, M.16
Tedder, T.F.17
Kiener, P.18
Jallal, B.19
Wu, H.20
Coyle, A.J.21
more..
-
112
-
-
0035794194
-
High resolution mapping of the binding site on human IgG1 for FcRI, FcRII, FcRIII, and FcRn and design of IgG1 variants with improved binding to the FcR
-
Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG. 2001. High resolution mapping of the binding site on human IgG1 for Fc(RI, Fc(RII, Fc(RIII, and FcRn and design of IgG1 variants with improved binding to the Fc(R. J Biol Chem 276:6591-6604.
-
(2001)
J Biol Chem
, vol.276
, pp. 6591-6604
-
-
Shields, R.L.1
Namenuk, A.K.2
Hong, K.3
Meng, Y.G.4
Rae, J.5
Briggs, J.6
Xie, D.7
Lai, J.8
Stadlen, A.9
Li, B.10
Fox, J.A.11
Presta, L.G.12
-
113
-
-
33645218704
-
Engineered antibody Fc variants with enhanced effector function
-
Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI. 2006. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103:4005-4010.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 4005-4010
-
-
Lazar, G.A.1
Dang, W.2
Karki, S.3
Vafa, O.4
Peng, J.S.5
Hyun, L.6
Chan, C.7
Chung, H.S.8
Eivazi, A.9
Yoder, S.C.10
Vielmetter, J.11
Carmichael, D.F.12
Hayes, R.J.13
Dahiyat, B.I.14
-
114
-
-
34548770705
-
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors
-
Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S. 2007. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 67:8882-8890.
-
(2007)
Cancer Res
, vol.67
, pp. 8882-8890
-
-
Stavenhagen, J.B.1
Gorlatov, S.2
Tuaillon, N.3
Rankin, C.T.4
Li, H.5
Burke, S.6
Huang, L.7
Vijh, S.8
Johnson, S.9
Bonvini, E.10
Koenig, S.11
-
115
-
-
20944442617
-
Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis
-
Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J, Qureshi F, Sandlund B, Kawaguchi L, Dummer W, Lowman H, McKeever K. 2005. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother 28:212-219.
-
(2005)
J Immunother
, vol.28
, pp. 212-219
-
-
Vugmeyster, Y.1
Beyer, J.2
Howell, K.3
Combs, D.4
Fielder, P.5
Yang, J.6
Qureshi, F.7
Sandlund, B.8
Kawaguchi, L.9
Dummer, W.10
Lowman, H.11
McKeever, K.12
-
116
-
-
33750622479
-
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
-
Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ, Breitmeyer JB, Weiner GJ. 2006. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108:2648-2654.
-
(2006)
Blood
, vol.108
, pp. 2648-2654
-
-
Bowles, J.A.1
Wang, S.Y.2
Link, B.K.3
Allan, B.4
Beuerlein, G.5
Campbell, M.A.6
Marquis, D.7
Ondek, B.8
Wooldridge, J.E.9
Smith, B.J.10
Breitmeyer, J.B.11
Weiner, G.J.12
-
117
-
-
0035865063
-
Engineered antibodies with increased activity to recruit complement
-
Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, Mulkerrin MG. 2001. Engineered antibodies with increased activity to recruit complement. J Immunol 166:2571-2575.
-
(2001)
J Immunol
, vol.166
, pp. 2571-2575
-
-
Idusogie, E.E.1
Wong, P.Y.2
Presta, L.G.3
Gazzano-Santoro, H.4
Totpal, K.5
Ultsch, M.6
Mulkerrin, M.G.7
-
118
-
-
77953659426
-
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
-
Moore GL, Chen H, Karki S, Lazar GA. 2010. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2:181-189.
-
(2010)
MAbs
, vol.2
, pp. 181-189
-
-
Moore, G.L.1
Chen, H.2
Karki, S.3
Lazar, G.A.4
-
119
-
-
45549090117
-
Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities
-
Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K,Wakitani M, Ohta S, Satoh M, Shitara K, Niwa R. 2008. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 68:3863-3872.
-
(2008)
Cancer Res
, vol.68
, pp. 3863-3872
-
-
Natsume, A.1
In, M.2
Takamura, H.3
Nakagawa, T.4
Shimizu, Y.5
Kitajima, K.6
Wakitani, M.7
Ohta, S.8
Satoh, M.9
Shitara, K.10
Niwa, R.11
-
120
-
-
84874041029
-
Natalizumab: Bench to bedside and beyond
-
Rudick R, Polman C, Clifford D, Miller D, Steinman L. 2013.Natalizumab: Bench to bedside and beyond. JAMA Neurol 70:172-182.
-
(2013)
JAMA Neurol
, vol.70
, pp. 172-182
-
-
Rudick, R.1
Polman, C.2
Clifford, D.3
Miller, D.4
Steinman, L.5
-
121
-
-
84858683384
-
Denosumab for treatment of breast cancer bone metastases and beyond
-
Nangia JR, Ma JD, Nguyen CM, Mendes MA, Trivedi MV. 2012.Denosumab for treatment of breast cancer bone metastases and beyond. Expert Opin Biol Ther 12:491-501.
-
(2012)
Expert Opin Biol Ther
, vol.12
, pp. 491-501
-
-
Nangia, J.R.1
Ma, J.D.2
Nguyen, C.M.3
Mendes, M.A.4
Trivedi, M.V.5
-
122
-
-
84920031180
-
In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates
-
Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Singh S, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ. 2014. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2:846-856.
-
(2014)
Cancer Immunol Res
, vol.2
, pp. 846-856
-
-
Wang, C.1
Thudium, K.B.2
Han, M.3
Wang, X.T.4
Huang, H.5
Feingersh, D.6
Garcia, C.7
Wu, Y.8
Kuhne, M.9
Srinivasan, M.10
Singh, S.11
Wong, S.12
Garner, N.13
Leblanc, H.14
Bunch, R.T.15
Blanset, D.16
Selby, M.J.17
Korman, A.J.18
-
123
-
-
84908218494
-
Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes
-
DEFEND Investigator Group.
-
Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, Pozzilli P; DEFEND Investigator Group. 2014. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 37:2746-2754.
-
(2014)
Diabetes Care
, vol.37
, pp. 2746-2754
-
-
Aronson, R.1
Gottlieb, P.A.2
Christiansen, J.S.3
Donner, T.W.4
Bosi, E.5
Bode, B.W.6
Pozzilli, P.7
-
124
-
-
77953652926
-
IgG2m4, an engineered antibody isotype with reduced Fc function
-
An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, Vitelli S, Zhao JZ, Lu P, Hua J, Gibson CR, Harvey BR, Montgomery D, Zaller D, Wang F, Strohl W. 2009. IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs 1:572-579.
-
(2009)
MAbs
, vol.1
, pp. 572-579
-
-
An, Z.1
Forrest, G.2
Moore, R.3
Cukan, M.4
Haytko, P.5
Huang, L.6
Vitelli, S.7
Zhao, J.Z.8
Lu, P.9
Hua, J.10
Gibson, C.R.11
Harvey, B.R.12
Montgomery, D.13
Zaller, D.14
Wang, F.15
Strohl, W.16
-
125
-
-
29644434678
-
An engineered human IgG1 antibody with longer serum halflife
-
Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. 2006. An engineered human IgG1 antibody with longer serum halflife. J Immunol 176:346-356.
-
(2006)
J Immunol
, vol.176
, pp. 346-356
-
-
Hinton, P.R.1
Xiong, J.M.2
Johlfs, M.G.3
Tang, M.T.4
Keller, S.5
Tsurushita, N.6
-
126
-
-
33747631571
-
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
-
Dall'Acqua WF, Kiener PA, Wu H. 2006. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514-23524.
-
(2006)
J Biol Chem
, vol.281
, pp. 23514-23524
-
-
Dall'Acqua, W.F.1
Kiener, P.A.2
Wu, H.3
-
127
-
-
76349123565
-
Enhanced antibody half-life improves in vivo activity
-
Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. 2010. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28:157-159.
-
(2010)
Nat Biotechnol
, vol.28
, pp. 157-159
-
-
Zalevsky, J.1
Chamberlain, A.K.2
Horton, H.M.3
Karki, S.4
Leung, I.W.5
Sproule, T.J.6
Lazar, G.A.7
Roopenian, D.C.8
Desjarlais, J.R.9
-
128
-
-
0842264005
-
Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
-
Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC.2004. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103:1472-1474.
-
(2004)
Blood
, vol.103
, pp. 1472-1474
-
-
Farag, S.S.1
Flinn, I.W.2
Modali, R.3
Lehman, T.A.4
Young, D.5
Byrd, J.C.6
-
129
-
-
19944425937
-
FCGR3A and FCGR2A polymorphisms
-
may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.
-
Lin TS, Flinn IW, Modali R, Lehman TA, Webb J, Waymer S, Moran ME, Lucas MS, Farag SS, Byrd JC. 2005. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 105:289-291.
-
(2005)
Blood
, vol.105
, pp. 289-291
-
-
Lin, T.S.1
Flinn, I.W.2
Modali, R.3
Lehman, T.A.4
Webb, J.5
Waymer, S.6
Moran, M.E.7
Lucas, M.S.8
Farag, S.S.9
Byrd, J.C.10
-
130
-
-
34548509226
-
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with singleagent cetuximab
-
Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. 2007. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with singleagent cetuximab. J Clin Oncol 25:3712-3718.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3712-3718
-
-
Zhang, W.1
Gordon, M.2
Schultheis, A.M.3
Yang, D.Y.4
Nagashima, F.5
Azuma, M.6
Chang, H.M.7
Borucka, E.8
Lurje, G.9
Sherrod, A.E.10
Iqbal, S.11
Groshen, S.12
Lenz, H.J.13
|